201 related articles for article (PubMed ID: 27650511)
1. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
Tang FF; Xu LP; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Yan CH; Sun YQ; Mo XD; Liu KY; Huang XJ
Br J Haematol; 2018 Feb; 180(3):448-451. PubMed ID: 27650511
[No Abstract] [Full Text] [Related]
2. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.
Qin YZ; Xu LP; Chen H; Jiang Q; Wang Y; Jiang H; Zhang XH; Han W; Chen YH; Wang FR; Wang JZ; Zhu HH; Liu YR; Jiang B; Liu KY; Huang XJ
Leuk Lymphoma; 2015; 56(11):3116-23. PubMed ID: 25804769
[TBL] [Abstract][Full Text] [Related]
3. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Duan W; Liu X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Zhao X; Qin Y; Shi H; Chang Y; Huang X; Jiang H
Br J Haematol; 2021 Jan; 192(2):265-271. PubMed ID: 32588434
[TBL] [Abstract][Full Text] [Related]
4. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
[No Abstract] [Full Text] [Related]
5. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
6. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
7. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
Cho BS; Min GJ; Park SS; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Bone Marrow Transplant; 2021 Nov; 56(11):2682-2689. PubMed ID: 34183780
[TBL] [Abstract][Full Text] [Related]
9. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
[TBL] [Abstract][Full Text] [Related]
10. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
Schwind S; Edwards CG; Nicolet D; Mrózek K; Maharry K; Wu YZ; Paschka P; Eisfeld AK; Hoellerbauer P; Becker H; Metzeler KH; Curfman J; Kohlschmidt J; Prior TW; Kolitz JE; Blum W; Pettenati MJ; Dal Cin P; Carroll AJ; Caligiuri MA; Larson RA; Volinia S; Marcucci G; Bloomfield CD;
Blood; 2013 Jan; 121(2):385-91. PubMed ID: 23160462
[TBL] [Abstract][Full Text] [Related]
11. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
12. Marked eosinophilia with abnormal basophilic granules in acute graft-versus-host disease post-allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without CBFB-MYH11 mutation.
Chew E; Mason KD; Juneja S
Eur J Haematol; 2013 Feb; 90(2):175-6. PubMed ID: 23106290
[No Abstract] [Full Text] [Related]
13. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
Guièze R; Renneville A; Cayuela JM; Abdelali RB; Boissel N; de Botton S; Rubio MT; Mazingue F; Macintyre EA; Cheok M; Sigaux F; Fenaux P; Dombret H; Preudhomme C
Leukemia; 2010 Jul; 24(7):1386-8. PubMed ID: 20508610
[No Abstract] [Full Text] [Related]
14. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
19. 3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
Tang G; Zou Y; Wang SA; Borthakur G; Toruner G; Hu S; Li S; Xu J; Medeiros LJ; Tang Z
Ann Hematol; 2022 Apr; 101(4):847-854. PubMed ID: 35184217
[TBL] [Abstract][Full Text] [Related]
20. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]